Gain in US prostate cancer sales disappoints Telix investors
MELBOURNE: ASX-listed biotech Telix Pharmaceuticals has reported a near 40 per cent sales uplift of
MELBOURNE: ASX-listed biotech Telix Pharmaceuticals has reported a near 40 per cent sales uplift of